NASDAQ
Castle Biosciences, Inc. (CSTL)
♥ 355 Thanks from members
Castle Biosciences (CSTL) exhibits a mix of strong Q2 2026 revenue growth surging 20% to $103 million alongside compressed gross margins, a net loss of $2.1 million, and lingering uncertainty regarding Medicare coverage timelines for DecisionDx-SCC.